Dr David Mazer (University of Toronto, Toronto, CA) discusses the effect of empagliflozin on erythropoietin levels, iron stores and red blood cell morphology in patients with type 2 diabetes and coronary artery disease.
1. Why did you conduct this research?
2. How did you collect and analyse these data and what was the patient population?
3. What were your findings?
4. How should these data be interpreted and what can they teach us?
Filmed live on site at AHA 2019 by Radcliffe Cardiology.
Interviewer: Liam O'Neill
Videographer: Tom Green & Dominic Woodruff